Natera experienced upward trading momentum accompanied by intraday volatility, driven primarily by strong investor sentiment following the company’s presentation at the Morgan Stanley Annual Global Healthcare Conference. During the event, executive leadership detailed sustained high-volume adoption for its flagship minimal residual disease test, Signatera, alongside expanding market penetration in women’s health and organ health diagnostics. Positive updates regarding expanding coverage under national clinical guidelines and favorable Medicare reimbursement policy updates further underscored the company’s market positioning and long-term commercial runway in precision oncology.

Investor enthusiasm has been reinforced by operational…